$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
乐伐替尼治疗肝癌有效率为37%
2025-10-19 11:44:20
Check Details
多吉美多久会产生耐药性?
2025-10-19 11:44:20
Check Details
卡博替尼晚期肝癌二线治疗选择
2025-10-19 11:44:20
Check Details
瑞格非尼(Regorafenib)肝癌靶向药物
2025-10-19 11:44:20
Check Details
多吉美适应于晚期无法手术的肝癌患者
2025-10-19 11:44:20
Check Details
卡博替尼适应症之肝癌
2025-10-19 11:44:20
Check Details
索拉菲尼作用机制说明
2025-10-19 11:44:20
Check Details
多吉美抗肿瘤治疗之肝癌
2025-10-19 11:44:20
Check Details
多吉美抗肿瘤治疗的总结
2025-10-19 11:44:20
Check Details
舒尼替尼临床研究之肝癌
2025-10-19 11:44:20
Check Details
索拉菲尼在进展期原发性肝癌中的应用
2025-10-19 11:44:20
Check Details
索拉菲尼治疗原发性肝癌作用机制之阻断RAF激酶
2025-10-19 11:44:20
Check Details
1
2
...
2565
2566
2567
2568
2569
2570
2571
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
2
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
5
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
6
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
9
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
10
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
11
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
12
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained